FilingReader Intelligence
Zai Lab reports 9% revenue growth to $110m
August 7, 2025 at 11:09 AM UTC•By FilingReader AI
Zai Lab reported Q2 2025 revenues of $109.977 million, up 9% year-over-year, driven by strong VYVGART, XACDURO, and NUZYRA sales. Operating loss improved 28% to $54.895 million.
The company reported positive ZL-1310 data and plans regulatory submission for bemarituzumab.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
HKEX:9688•Hong Kong Exchange
News Alerts
Get instant email alerts when Zai Lab publishes news
Free account required • Unsubscribe anytime